Qaiser Bashir, MD
Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Professor, Department of Stem Cell Transplantation, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2023 | Duke Fuqua School of Business, Durham, NC, USA, MS, Master's in Health Analytics |
| 2001 | King Edward Medical University, Lahore, PAK, MD, Bachelor of Medicine and Bachelor of Surgery |
Postgraduate Training
| 2009-2010 | Clinical Fellowship, Stem Cell Transplantation and Cellular Therapy, University of Texas M. D. Anderson Cancer Center, Houston, TX |
| 2006-2009 | Clinical Fellowship, Hematology/Oncology, University of Colorado Health Sciences Center, Denver, CO |
| 2004-2006 | Clinical Residency, Internal Medicine, University of Missouri-Columbia, Columbia, MO |
| 2003-2004 | Clinical Internship, Internal Medicine, University of Missouri-Columbia, Columbia, MO |
Board Certifications
| 2009 | American Board of Internal Medicine - Medical Oncology |
| 2009 | American Board of Internal Medicine - Hematology |
| 2006 | American Board of Internal Medicine - Internal Medicine |
Experience & Service
Administrative Appointments/Responsibilities
FACT Immune Effector Cell Inspector, The University of Texas MD Anderson Cancer Center, Houston, TX, 2017 - Present
Fellowship Program Director, Department of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX, 2012 - Present
Other Appointments/Responsibilities
Member, CIBMT Plasma Cell Disorder & Adult Solid Tumors Working Committee, Milwaukee, WI, 2015 - Present
Member, CIBMTR Acute Leukemia Working Committee, Milwaukee, WI, 2010 - Present
Member, CIBMTR NHL Working Committee, Milwaukee, WI, 2010 - Present
Member, Protocol Review and Monitoring Committee, Denver, CO, 2006 - 2009
Institutional Committee Activities
Associate Member, Institutional Review Board (IRB) 2, 2020 - Present
Member, Clinical Research Committee #2, 2014 - Present
Provider Officer, EHR, 2014 - Present
Member, Clinical Research Committee #3, 2013 - 2014
Member, 9th Annual Employee Recognition & Awards Committee, 2012 - 2013
Member, Graduate Medical Education Committee, 2012 - Present
Member, Graduate Medical Education Budget Subcommittee, 2012 - Present
Selected Publications
Peer-Reviewed Articles
- Ciurea SO, Mulanovich V, Saliba RM, Bayraktar UD, Jiang Y, Bassett R, Wang SA, Konopleva M, Fernandez-Vina M, Montes N, Bosque D, Chen J, Rondon G, Alatrash G, Alousi A, Bashir Q, Korbling M, Qazilbash M, Parmar S, Shpall E, Nieto Y, Hosing C, Kebriaei P, Khouri I, Popat U, de Lima M, Champlin RE. Improved Early Outcomes Using a T Cell Replete Graft Compared with T Cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 18(12):1835-44, 2012. e-Pub 2012. PMID: 22796535.
- Nieto Y, Thall P, Valdez B, Andersson B, Popat U, Anderlini P, Shpall EJ, Bassett R, Alousi A, Hosing C, Kebriaei P, Qazilbash M, Frazier E, Gulbis A, Chancoco C, Bashir Q, Ciurea S, Khouri I, Parmar S, Shah N, Worth L, Rondon G, Champlin R, Jones RB. High-Dose Infusional Gemcitabine Combined with Busulfan and Melphalan with Autolgous Stem-Cell Transplantation in Patients with Refractory Lymphoid Malignancies. Biol Blood Marrow Transplant 18(11):1677-86, 2012. e-Pub 2012. PMID: 22643322.
- Beitinjaneh AM, Saliba R, Bashir Q, Shah N, Parmar S, Hosing C, Popat U, Anderlini P, Dinh Y, Qureshi S, Rondon G, Champlin RE, Giralt SA, Qazilbash MH. Durable Responses after Donor Lymphocyte Infusion for Patients with Residual Multiple Myeloma following Non-Myeloablative Allogeneic Stem Cell Transplantation. Leuk Lymphoma 53(8):1525-1529, 2012. e-Pub 2012. PMID: 22242817.
- Shah N, Ahmed F, Bashir Q, Qureshi S, Dinh Y, Rondon G, Wen S, Thall P, Khan H, Giralt S, Champlin R, Qazilbash MH. Durable Remission with Salvage Autotransplants in Patients with Multiple Myeloma. Cancer 118(14):3549-55, 2012. e-Pub 2011. PMID: 22086552.
- Khouri IF, Saliba RM, Erwin WD, Samuels BI, Korbling M, Medeiros LJ, Valverde R, Alousi AM, Anderlini P, Bashir Q, Ciurea S, Gulbis AM, de Lima M, Hosing C, Kebriaei P, Popat UR, Fowler N, Neelapu SS, Samaniego F, Champlin RE, Macapinlac HA. Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results. Blood 119(26):6373-8, 2012. e-Pub 2012. PMID: 22586182.
- Sharma M, Khan H, Thall PF, Orlowski RZ, Bassett RL, Shah N, Bashir Q, Parmar S, Wang M, Shah JJ, Hosing CM, Popat UR, Giralt SA, Champlin RE, Qazilbash MH. A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid. Cancer 118(9):2507-15, 2012. e-Pub 2011. PMID: 21887685.
- Bashir Q, Munsell MF, Giralt S, de Padua Silva L, Sharma M, Couriel D, Chiattone A, Popat U, Qazilbash MH, Fernandez-Vina M, Champlin RE, de Lima MJ. Randomized phase II trial comparing two dose levels of thymoglobulin in patients undergoing unrelated donor hematopoietic cell transplant. Leuk Lymphoma 53(5):915-919, 2012. e-Pub 2011. PMID: 22023525.
- Bashir Q, Khan H, Orlowski RZ, Amjad AI, Shah N, Parmar S, Wei W, Rondon G, Weber DM, Wang M, Thomas SK, Shah JJ, Qureshi SR, Dinh YT, Popat U, Anderlini P, Hosing C, Giralt S, Champlin RE, Qazilbash MH. Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma. Am J Hematol 87(3):272-276, 2012. e-Pub 2012. PMID: 22231283.
- Bashir Q, Shah N, Parmar S, Wei W, Rondon G, Weber DM, Wang M, Orlowski RZ, Thomas SK, Shah J, Qureshi SR, Dinh YT, Popat U, Anderlini P, Hosing C, Giralt S, Champlin RE, Qazilbash MH. Feasibility of autologous hematopoietic stem cell transplant in patients aged greater than 70 years with multiple myeloma. Leuk Lymphoma 53(1):118-22, 2012. e-Pub 2011. PMID: 21780997.
- Sharma M, Ravandi F, Bayraktar UD, Chiattone A, Bashir Q, Giralt S, Chen J, Qazilbash M, Kebriaei P, Konopleva M, Andreeff M, Cortes J, McCue D, Kantarjian H, Champlin RE, de Lima M. Treatment of FLT3-ITD Positive Acute Myeloid Leukemia Relapsing After Allogeneic Stem Cell Transplantation with Sorafenib. Biol Blood Marrow Transplant 17(12):1874-7, 2011. e-Pub 2011. PMID: 21767516.
- Bashir Q, Andersson BS, Fernandez-Vina M, de Padua Silva L, Giralt S, Chiattone A, Wei W, Sharma M, Anderlini P, Shpall EJ, Popat U, Rodrigues M, Champlin RE, de Lima M. Unrelated Donor Transplantation for Acute Myelogenous Leukemia in First Remission. Biol Blood Marrow Transplant 17(7):1067-71, 2011. e-Pub 2010. PMID: 21087679.
- Bashir Q, Langford LA, Parmar S, Champlin RE, Qazilbash MH. Primary systemic amyloid light chain amyloidosis decompensating after filgrastim-induced mobilization and stem-cell collection. J Clin Oncol 29(4):e79-e80, 2011. e-Pub 2010. PMID: 21060030.
- Bashir Q, De Lima MJ, McMannis JD, Garcia-Manero G, Shpall E, Kantarjian H, Cortes JE, O'Brien SM, Jones D, Qazilbash M, Wei W, Giralt SA, Champlin RE, Hosing C. Hematopoietic progenitor cell collection in patients with chronic myelogenous leukemia in complete cytogenetic remission after imatinib mesylate therapy. Leuk Lymphoma 51(8):1478-84, 2010. PMID: 20658954.
- Bashir Q, Lee CK, Stuart RW, Smith ML, Ryder J, Gonzalez R. Phenotypic evolution of Waldenstrom's macroglobulinemia to extramedullary plasmacytoma. J Clin Oncol 26(14):2408-2410, 2008. PMID: 18467735.
- Floyd JD, Nguyen DT, Lobins RL, Bashir Q, Doll DC, Perry MC. Cardiotoxicity of cancer therapy. J Clin Oncol 23(30):7685-96, 2005. PMID: 16234530.
- Govindarajan G, Bashir Q, Kuppuswamy S, Brooks C. Sweet syndrome associated with furosemide. South Med J 98(5):570-2, 2005. PMID: 15954518.
Patient Reviews
CV information above last modified November 25, 2024